tiprankstipranks
Trending News
More News >
enVVeno Medical (NVNO)
NASDAQ:NVNO

enVVeno Medical (NVNO) AI Stock Analysis

Compare
328 Followers

Top Page

NV

enVVeno Medical

(NASDAQ:NVNO)

58Neutral
enVVeno Medical's overall stock score is influenced by its robust technical performance, which is somewhat overshadowed by challenging financial metrics. The company faces significant profitability issues, as reflected by its negative income and cash flow figures, despite having a stable balance sheet. While technical indicators show strong upward momentum, valuation concerns due to a negative P/E ratio and lack of dividends weigh on the score.

enVVeno Medical (NVNO) vs. S&P 500 (SPY)

enVVeno Medical Business Overview & Revenue Model

Company DescriptionenVVeno Medical Corporation (NVNO) is a healthcare company specializing in the development of innovative medical devices aimed at addressing venous diseases. The company's primary focus is on creating solutions for venous valve disorders, with products designed to improve the quality of life for patients suffering from chronic venous insufficiency (CVI). enVVeno Medical operates in the medical device sector, leveraging advanced research and technology to deliver effective treatment options.
How the Company Makes MoneyenVVeno Medical makes money by developing, manufacturing, and selling medical devices designed to treat venous diseases. The company's primary revenue stream comes from the sales of its proprietary products aimed at improving venous valve function, particularly for patients with chronic venous insufficiency. Key factors contributing to its earnings include product sales to healthcare providers, partnerships with medical institutions for clinical trials and product distribution, and potentially licensing or royalty agreements related to its patented technologies. The company's ability to generate revenue is closely tied to the successful commercialization of its products and the establishment of strategic partnerships within the healthcare industry.

enVVeno Medical Financial Statement Overview

Summary
enVVeno Medical faces significant financial challenges, marked by substantial losses and negative cash flows. The income statement shows severe profitability issues with highly negative margins. The balance sheet, however, indicates strong financial stability due to low leverage and high equity. Cash flow analysis reveals insufficient cash flow generation from operations, necessitating strategic initiatives for improvement.
Income Statement
25
Negative
enVVeno Medical's income statement reveals a challenging financial position. The company has only recently generated revenue in the TTM period, with a gross profit margin of 17.37%. However, net income remains significantly negative, resulting in a net profit margin of -2626.72%. The EBIT and EBITDA margins also indicate substantial losses, at -2866.26% and -2819.95% respectively. These figures highlight ongoing operational challenges and a need for strategic shifts to improve profitability.
Balance Sheet
60
Neutral
The balance sheet of enVVeno Medical shows a strong equity position with a low debt-to-equity ratio of 0.03, indicating minimal leverage and financial risk. The equity ratio stands at 94.40%, underlining substantial equity financing. However, the company's return on equity is negative at -55.68%, reflecting the impact of net losses. Despite the robust equity standing, profitability remains a significant concern.
Cash Flow
50
Neutral
The cash flow analysis for enVVeno Medical reflects negative operating and free cash flows, with a free cash flow growth rate of -2.73% from the previous year. The operating cash flow to net income ratio is 0.81 for the TTM period, indicating that cash flows are not sufficient to cover net losses. While financing activities have contributed positively, the company must improve cash flow generation from operations to sustain long-term viability.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.000.000.00
Gross Profit
0.00-546.00K-525.00K-452.91K-383.97K
EBIT
-23.83M-25.24M-24.93M-16.89M-9.14M
EBITDA
-21.29M-25.02M-24.51M-16.75M-8.75M
Net Income Common Stockholders
-21.82M-23.52M-24.30M-16.20M-8.92M
Balance SheetCash, Cash Equivalents and Short-Term Investments
43.15M46.41M39.04M54.73M9.33M
Total Assets
44.95M48.63M41.66M57.70M10.54M
Total Debt
1.06M1.40M1.72M2.01M880.65K
Net Debt
-690.00K-2.22M-2.84M-52.72M-8.45M
Total Liabilities
2.79M2.44M2.93M3.29M3.44M
Stockholders Equity
42.16M46.20M38.73M54.40M7.10M
Cash FlowFree Cash Flow
-16.88M-18.89M-15.73M-12.21M-7.86M
Operating Cash Flow
-16.84M-18.86M-15.62M-11.85M-7.68M
Investing Cash Flow
1.33M-7.87M-34.55M-367.89K-180.29K
Financing Cash Flow
13.64M25.79M0.0057.61M15.07M

enVVeno Medical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.55
Price Trends
50DMA
2.82
Positive
100DMA
2.98
Positive
200DMA
3.66
Negative
Market Momentum
MACD
0.08
Negative
RSI
73.15
Negative
STOCH
95.84
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVNO, the sentiment is Positive. The current price of 3.55 is above the 20-day moving average (MA) of 2.52, above the 50-day MA of 2.82, and below the 200-day MA of 3.66, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 73.15 is Negative, neither overbought nor oversold. The STOCH value of 95.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVNO.

enVVeno Medical Risk Analysis

enVVeno Medical disclosed 35 risk factors in its most recent earnings report. enVVeno Medical reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

enVVeno Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
$62.25M-52.88%29.64%
57
Neutral
$49.27M-158.63%57.09%52.18%
52
Neutral
$5.36B3.88-42.93%2.87%17.85%1.45%
52
Neutral
$40.35M-159.87%18.56%32.65%
47
Neutral
$47.24M-114.70%-8.11%-23.04%
39
Underperform
$49.05M-87.40%-1455.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NVNO
enVVeno Medical
3.55
-1.54
-30.26%
APYX
Apyx Medical
1.25
-0.15
-10.71%
ECOR
Electrocore
6.85
-0.15
-2.14%
TELA
TELA Bio
1.02
-3.57
-77.78%
RBOT
Vicarious Surgical
8.27
-0.76
-8.42%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.